Related Experiment Video
Updated: Jul 5, 2026
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
Severe recurrent hypoglycemia after gastric bypass surgery
Kaspar Z'graggen1, Ahmed Guweidhi, Rudolf Steffen
1Berner Viszeralchirurgie and Schweizerisches Pankreaszentrum Klinik Beau-Site Bern, Bern, Switzerland.
Obesity Surgery
|April 29, 2008
Summary
Restoring gastric restriction surgically can effectively treat severe hypoglycemia after gastric bypass surgery (GBS). This approach resolves symptoms in most patients, making distal pancreatectomy a secondary treatment option.
Area of Science:
- Endocrinology
- Bariatric Surgery
- Gastroenterology
Background:
- Bariatric surgery is highly effective for long-term weight loss in severe obesity.
- Severe recurrent hyperinsulinemic hypoglycemia is a rare complication following gastric bypass surgery (GBS).
- Pancreatic nesidioblastosis was previously suspected as the cause, with pancreatectomy as the proposed treatment.
Purpose of the Study:
- To investigate if restoring gastric restriction can treat severe hypoglycemia post-GBS.
- To evaluate the efficacy of surgical restoration of gastric restriction for hypoglycemia after GBS.
Main Methods:
- 12 consecutive patients with severe hypoglycemia post-GBS underwent surgical restoration of gastric restriction.
- Procedures included silastic ring placement (n=8) or adjustable gastric banding (n=4).
- Two patients initially received distal pancreatectomy along with silastic ring placement.
Main Results:
- After a median 7-month follow-up, 11 out of 12 patients were free of hypoglycemic episodes.
- One patient experienced recurrent hypoglycemia and subsequently underwent distal pancreatectomy.
- The procedural mortality rate was 0%, with a morbidity rate of 8.3%.
Conclusions:
- Restoration of gastric restriction is a primary, effective treatment for severe recurrent hypoglycemia after GBS.
- Distal pancreatectomy should be reserved as a second-line treatment option for persistent cases.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:21Hyperosmolar Hyperglycemic State
Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.